These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8099964)

  • 1. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats.
    Kawato Y; Sekiguchi M; Akahane K; Tsutomi Y; Hirota Y; Kuga H; Suzuki W; Hakusui H; Sato K
    J Pharm Pharmacol; 1993 May; 45(5):444-8. PubMed ID: 8099964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.
    Harel M; Hyatt JL; Brumshtein B; Morton CL; Yoon KJ; Wadkins RM; Silman I; Sussman JL; Potter PM
    Mol Pharmacol; 2005 Jun; 67(6):1874-81. PubMed ID: 15772291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.
    Hyatt JL; Tsurkan L; Morton CL; Yoon KJ; Harel M; Brumshtein B; Silman I; Sussman JL; Wadkins RM; Potter PM
    Chem Biol Interact; 2005 Dec; 157-158():247-52. PubMed ID: 16257398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: a preclinical study.
    Blandizzi C; De Paolis B; Colucci R; Di Paolo A; Danesi R; Del Tacca M
    Toxicol Appl Pharmacol; 2001 Dec; 177(2):149-56. PubMed ID: 11740913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
    Takeda Y; Kobayashi K; Akiyama Y; Soma T; Handa S; Kudoh S; Kudo K
    Int J Cancer; 2001 Apr; 92(2):269-75. PubMed ID: 11291056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables.
    Dodds HM; Hanrahan J; Rivory LR
    Anticancer Drug Des; 2001; 16(4-5):239-46. PubMed ID: 12049482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues.
    Kim DK; Ryu DH; Lee JY; Lee N; Kim YW; Kim JS; Chang K; Im GJ; Kim TK; Choi WS
    J Med Chem; 2001 May; 44(10):1594-602. PubMed ID: 11334569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
    Ikuno N; Soda H; Watanabe M; Oka M
    J Natl Cancer Inst; 1995 Dec; 87(24):1876-83. PubMed ID: 7494232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.
    Blandizzi C; De Paolis B; Colucci R; Lazzeri G; Baschiera F; Del Tacca M
    Br J Pharmacol; 2001 Jan; 132(1):73-84. PubMed ID: 11156563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel agents that potentially inhibit irinotecan-induced diarrhea.
    Yang X; Hu Z; Chan SY; Chan E; Goh BC; Duan W; Zhou S
    Curr Med Chem; 2005; 12(11):1343-58. PubMed ID: 15975002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11).
    Dodds HM; Rivory LP
    Mol Pharmacol; 1999 Dec; 56(6):1346-53. PubMed ID: 10570064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
    Shimada Y; Rothenberg M; Hilsenbeck SG; Burris HA; Degen D; Von Hoff DD
    Anticancer Drugs; 1994 Apr; 5(2):202-6. PubMed ID: 8049503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
    Rivory LP; Riou JF; Haaz MC; Sable S; Vuilhorgne M; Commerçon A; Pond SM; Robert J
    Cancer Res; 1996 Aug; 56(16):3689-94. PubMed ID: 8706009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats.
    Yokooji T; Kawabe Y; Mori N; Murakami T
    J Pharm Pharmacol; 2013 Feb; 65(2):280-91. PubMed ID: 23278696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
    Bonneterre J
    Bull Cancer; 1995 Aug; 82(8):623-8. PubMed ID: 7492818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
    Kawato Y; Aonuma M; Hirota Y; Kuga H; Sato K
    Cancer Res; 1991 Aug; 51(16):4187-91. PubMed ID: 1651156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
    Tanizawa A; Fujimori A; Fujimori Y; Pommier Y
    J Natl Cancer Inst; 1994 Jun; 86(11):836-42. PubMed ID: 8182764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.